PD06-06 IMPORTANCE OF [-2] PROPSA MEASUREMENT IN A DIAGNOSIS OF PROSTATE CANCER: PROSTATE HEALTH INDEX TRIAL (PROPHET) - DIAGNOSTIC IMPACTS OF CLINICAL LABORATORY-BASED INDICES ON GLEASON GRADE GROUP ≥2 OR ≥3 CANCER

Abstract

You have accessJournal of UrologyProstate Cancer: Detection & Screening I1 Apr 2018PD06-06 IMPORTANCE OF [-2] PROPSA MEASUREMENT IN A DIAGNOSIS OF PROSTATE CANCER: PROSTATE HEALTH INDEX TRIAL (PROPHET) - DIAGNOSTIC IMPACTS OF CLINICAL LABORATORY-BASED INDICES ON GLEASON GRADE GROUP ≥2 OR ≥3 CANCER Kazuto Ito, Akira Yokomizo, Shoji Tokunaga, Gaku Arai, Mikio Sugimoto, Koichiro Akakura, Hisashi Hasumi, Hideki Sakai, Akiko Ouraji, and Kazuhiro Suzuki Kazuto ItoKazuto Ito More articles by this author , Akira YokomizoAkira Yokomizo More articles by this author , Shoji TokunagaShoji Tokunaga More articles by this author , Gaku AraiGaku Arai More articles by this author , Mikio SugimotoMikio Sugimoto More articles by this author , Koichiro AkakuraKoichiro Akakura More articles by this author , Hisashi HasumiHisashi Hasumi More articles by this author , Hideki SakaiHideki Sakai More articles by this author , Akiko OurajiAkiko Ouraji More articles by this author , and Kazuhiro SuzukiKazuhiro Suzuki More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2018.02.426AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES PROPHET is a prospective study in order to clarify a diagnostic impact of laboratory-based and prostate volume-adjusted [-2] proPSA (p2PSA)-related indices on prostate cancer (PC) and a clinically significant PC with more than 2 positive biopsy cores or high Gleason Grade Group in the PSA below 10 ng/mL (Clinical trial No. UMIN000016934). METHODS Between April 2015 and March 2017, 421 men aged 50 to 79 who conducted 12 to 20-core prostate biopsy in the PSA range above age-specific cut-offs (3.0ng/ml, 3.5 ng/ml and 4.0 ng/ml, respectively, for age 50-64, 65-69 and 70-79) and below 10 ng/ml were registered in the PROPHET. Among those participants, 398 eligible men were investigated a diagnostic impact of various clinical laboratory-based free PSA-related and p2PSA-related indices on any grade, high volume and high Gleason grade group prostate cancer. RESULTS Among 398 men, 179 (45%), 141 (35%) and 80 (20%) were diagnosed with any grade PC, Gleason grade group ≥2 and ≥3 PC, respectively. Total AUC-ROC, partial AUC-ROC above 90% sensitivity (J Urol. 2005; 173: 425) and false positive rate (FPR) at 90% sensitivity for PSA, free/total PSA (%f-PSA), p2PSA/%f-PSA and prostate health index (phi) are shown in Table 1. Impacts of those various clinical laboratory-based indices on distinguishing non PC vs PC, Grade Group 1/ positive biopsy cores 0-2 vs remaining higher grade/ volume PC and Grade Group 1-2/ positive biopsy cores 0-2 vs remaining higher grade/ volume PC are indicated in Table 1. The total AUC-ROC and partial AUC-ROC above 90% sensitivity were larger in p2PSA-related indices than using PSA and %f-PSA in any comparisons indicated in Table 1. The FPRs at 90% sensitivity in p2PSA/%f-PSA and phi were superior to those in PSA and %f-PSA in any comparisons. phi would avoid unnecessary biopsy in 38% of men with PSA between the age-specific cut-offs and 10 ng/ml in the setting for detecting Grade Group 3-5 cancer or positive biopsy cores >2. CONCLUSIONS Clinical laboratory-based p2PSA-related indices would avoid in 35 to 41% of prostate biopsy in the setting not only for detecting any grade/ volume PC, but also for detecting clinically significant PC. © 2018FiguresReferencesRelatedDetailsCited byIto K, Yokomizo A, Tokunaga S, Arai G, Sugimoto M, Akakura K, Hasumi H, Sakai H, Ouraji A, Oki R, Kashiwagi E, Kobori Y, Hirama H, Kitoh H, Uemura H, Hakariya T and Suzuki K (2019) Diagnostic Impacts of Clinical Laboratory Based p2PSA Indexes on any Grade, Gleason Grade Group 2 or Greater, or 3 or Greater Prostate Cancer and Prostate Specific Antigen below 10 ng/mlJournal of Urology, VOL. 203, NO. 1, (83-91), Online publication date: 1-Jan-2020. Volume 199Issue 4SApril 2018Page: e152-e153 Advertisement Copyright & Permissions© 2018MetricsAuthor Information Kazuto Ito More articles by this author Akira Yokomizo More articles by this author Shoji Tokunaga More articles by this author Gaku Arai More articles by this author Mikio Sugimoto More articles by this author Koichiro Akakura More articles by this author Hisashi Hasumi More articles by this author Hideki Sakai More articles by this author Akiko Ouraji More articles by this author Kazuhiro Suzuki More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...